Bromocriptine and insulin secretion.
The dopaminergic drug bromocriptine inhibited the release of insulin from isolated mouse pancreatic islets. The effect was counteracted by haloperidol or pimozide. It is suggested that insulin release may be inhibited through activation of D-2 dopaminergic receptors in the pancreatic beta-cells.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010868:Pimozide / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects
D007328:Insulin; D011954:Receptors, Dopamine; D010868:Pimozide; D001971:Bromocriptine; D006220:Haloperidol